Johnson & Johnson (JNJ) Withdraws Cancer Drug Petition; Zeltia Group (18494051.MA) to Miss $10 Million Yondelis Payment After U.S. Setback
5/2/2011 7:13:58 AM
More...
|
Zeltia Group (18494051.MA) Fails to Win U.K. Backing for Ovarian Cancer Drug
3/11/2011 6:33:17 AM
More...
|
74 Percent EBITDA Improvement at Zeltia Group (18494051.MA) in 2010
2/25/2011 9:17:41 AM
More...
|
Australian Regulator Rejects Zeltia Group (18494051.MA)'s Cancer Drug Yondelis
11/12/2010 6:59:01 AM
More...
|
Zeltia Group (18494051.MA): Yondelis(R) Sales Expanded by 70 Percent
10/29/2010 7:03:53 AM
More...
|
Zeltia Group (18494051.MA) Reports Positive EBITDA in First Half of 2010
7/29/2010 11:53:18 AM
More...
|
Zeltia Group (18494051.MA) Achieves Consolidated EBITDA Break-Even in 1Q10
4/30/2010 12:47:00 PM
More...
|
Zeltia Group (18494051.MA) Achieves Consolidated EBITDA Break-Even in 1Q10
4/30/2010 10:20:34 AM
More...
|
Zeltia Group (18494051.MA) Revenues up 53.3%
2/26/2010 6:57:02 AM
More...
|
EU Agency Backs Zeltia Group (18494051.MA) Drug for Ovarian Cancer
9/25/2009 6:52:19 AM
More...
|
|